Astilbin reduces ROS accumulation and VEGF expression through Nrf2 in psoriasis-like skin disease

Biol Res. 2019 Sep 6;52(1):49. doi: 10.1186/s40659-019-0255-2.

Abstract

Background: Psoriasis is a common and intractable skin disease affecting the physical and mental health of patients. The accumulation of ROS is involved in the pathogenesis of psoriasis and antioxidants are believed to be therapeutic. This study aimed to investigate the therapeutic efficacy of astilbin on ROS accumulation in psoriasis.

Results: The study showed that 50 μg/ml astilbin could inhibit the growth and reduce the accumulation of ROS in HaCaT cells stimulated by IL-17 and TNF-α. Astilbin could elevate the Nrf2 accumulation in the nuclei, eventually leading to the transcriptional activation of various antioxidant proteins and reducing the expression of VEGF.

Conclusions: Our results collectively suggest that astilbin could induce Nrf2 nucleus translocation, which is contribute to reduce the ROS accumulation and VEGF expression, and inhibit the proliferation of HaCaT cells.

Keywords: Astilbin; Nrf2; Psoriasis; ROS.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Flavonols / administration & dosage*
  • Interleukin-17 / metabolism
  • Keratinocytes / drug effects*
  • Keratinocytes / metabolism
  • Male
  • Mice
  • Mice, Inbred BALB C
  • NF-E2-Related Factor 2 / drug effects*
  • NF-E2-Related Factor 2 / metabolism
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • Reactive Oxygen Species / metabolism*
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / drug effects
  • Tumor Necrosis Factor-alpha / metabolism
  • Vascular Endothelial Growth Factor A / drug effects*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Flavonols
  • Interleukin-17
  • NF-E2-Related Factor 2
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A
  • astilbin